Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoitesD A Herrington, Myron M. Levine, Dieter Gillessen et al.|Nature|1987Cited by 503
Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infectionJames R. Murphy, D. F. Clyde, Shahida Baqar et al.|Journal of Clinical Microbiology|1989Cited by 37
Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites.D A Herrington, R S Nussenzweig, D. F. Clyde et al.|PubMed|1990Cited by 27
Plasmodium falciparum: In vitro characterization and human infectivity of a cloned lineJonathan R. Davis, Joseph F. Cortese, D A Herrington et al.|Experimental Parasitology|1992Cited by 18
Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3Jonathan R. Davis, Myron Levine, James R. Murphy et al.|Transactions of the Royal Society of Tropical Medicine and Hygiene|1989Cited by 15